Multiple Sclerosis Clinical Trial

Clinical Trial Finder Multiple Sclerosis Trials

Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)

See Locations Near You

Summary

The objective of this active-drug Extension Study is to evaluate the continuing safety and efficacy of ONO-4641 (MSC2430913A) in subjects with relapsing-remitting multiple sclerosis (RRMS) who have completed an initial 26-week Core Study (ONO-4641POU006 [NCT01081782]).

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Completed 26 weeks of double-blind phase of Study ONO-4641POU006

Exclusion Criteria:

Presence of any dermatological abnormalities during Study ONO-4641POU006 that could increase the risk of the patient developing a skin cancer

Study is for people with:

Multiple Sclerosis

Phase:

Phase 2

Estimated Enrollment:

340

Study ID:

NCT01226745

Recruitment Status:

Terminated

Sponsor:

EMD Serono

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 56 Locations for this study

See Locations Near You

Tucson Clinical Site 133
Tucson Arizona, 85705, United States
Aurora Clinical Site 132
Aurora Colorado, 80045, United States
Fort Collins Clinical Site 123
Fort Collins Colorado, 80528, United States
Fairfield Clinical Site 110
Fairfield Connecticut, 06824, United States
Ormond Beach Clinical Site 129
Ormond Beach Florida, 32174, United States
Sarasota Clinical Site 116
Sarasota Florida, 34243, United States
Northbrook Clinical Site 135
Northbrook Illinois, 60062, United States
Fort Wayne Clinical Site 111
Fort Wayne Indiana, 46805, United States
Indianapolis Clinical Site 121
Indianapolis Indiana, 46202, United States
Detroit Clinical Site 104
Detroit Michigan, 48202, United States
Farmington Hills Clinical Site 126
Farmington Hills Michigan, 48334, United States
Lebanon Clinical Site 115
Lebanon New Hampshire, 03756, United States
Albuquerque Clinical Site 106
Albuquerque New Mexico, 87131, United States
Rochester Clinical Site 108
Rochester New York, 14642, United States
Charlotte Clinical Site 125
Charlotte North Carolina, 28201, United States
Raleigh Clinical Site 103
Raleigh North Carolina, 27607, United States
Akron Clinical Site 112
Akron Ohio, 44320, United States
Philadelphia Clinical Site 120
Philadelphia Pennsylvania, 19104, United States
Knoxville Clinical Site 134
Knoxville Tennessee, 37934, United States
Round Rock Clinical Site 107
Round Rock Texas, 78681, United States
Brugge Clinical Site 203
Brugge , 8000, Belgium
La Louviere Clinical Site 201
La Louviere , 8000, Belgium
Vancouver Clinical Site 131
Vancouver British Columbia, V6T 2, Canada
Gatineau Clinical Site 114
Gatineau Quebec, , Canada
Greenfield park Clinical Site 109
Greenfield Park Quebec, J4V2J, Canada
Montreal Clinical Site 101
Montreal Quebec, H1T2M, Canada
Montreal Clinical Site 102
Montreal , H9X3Z, Canada
Olomouc Clinical Site 212
Olomouc , 775 2, Czech Republic
Pardubice Clinical Site 211
Pardubice , 53203, Czech Republic
Praha 5 Clinical Site 213
Praha 5 , 15006, Czech Republic
Glessen Clinical Site 221
Glessen , 35385, Germany
Leipzig Clinical Site 229
Leipzig , 04103, Germany
Marburg Clinical Site 228
Marburg , 35033, Germany
Tubingen Clinical Site 226
Tubingen , 72076, Germany
Athens Clinical Site 243
Athens , 115 2, Greece
Kanto Region Clinical Site 404
Kanto , , Japan
Kanto Region Clinical Site 405
Kanto , , Japan
Kanto Region Clinical Site 406
Kanto , , Japan
Kanto Region Clinical Site 409
Kanto , , Japan
Kinki Region Clinical Site 401
Kinki , , Japan
Kinki Region Clinical Site 407
Kinki , , Japan
Kinki Region Clinical Site 408
Kinki , , Japan
Tohoku Region Clinical Site 403
Tohoku , , Japan
Tohoku Region Clinical Site 410
Tohoku , , Japan
Bialystok Clinical Site 305
Bialystok , 15-40, Poland
Czeladz Clinical Site 303
Czeladz , 41-25, Poland
Gdansk Clinical Site 302
Gdansk , 80-80, Poland
Katowice Clinical Site 309
Katowice , 40-59, Poland
Krakow Clinical Site 307
Krakow , 31-53, Poland
Lodz Clinical Site 306
Lodz , 90-15, Poland
Plewiska Clinical Site 304
Plewiska , 62-06, Poland
Warszawa Clinical Site 308
Warszawa , 04-74, Poland
Kazan Clinical Site 333
Kazan , 42010, Russian Federation
Moscow Clinical Site 332
Moscow , 10715, Russian Federation
Moscow Clinical Site 330
Moscow , 12135, Russian Federation
Nizhniy Novgorod Clinical Site 321
Nizhniy Novgorod , 10715, Russian Federation
Novosibirsk Clinical Site 324
Novosibirsk , 63009, Russian Federation
Samara Clinical Site 329
Samara , 44309, Russian Federation
St. Petersburg Clinical Site 325
St. Petersburg , 19435, Russian Federation
Ufa Clinical Site 326
Ufa , 45000, Russian Federation
Barcelona Clinical Site 252
Barcelona , 08025, Spain
Barcelona Clinical Site 253
Barcelona , 08025, Spain
Bilbao Clinical Site 255
Bilbao , 48013, Spain
Girona Clinical Site 254
Girona , 17007, Spain
Hospitalet de Llobregat Clinical Site 251
Hospitalet de Llobregat , 08907, Spain
Sevilla Clinical Site 256
Sevilla , 41071, Spain
Dnipropetrovsk Clinical Site 341
Dnipropetrovsk , 49027, Ukraine
Kyiv Clinical Site 344
Kyiv , 03110, Ukraine
Lviv Clinical Site 343
Lviv , 03110, Ukraine
Vinnytsya Clinical Site 342
Vinnytsya , 21005, Ukraine
Load More

How clear is this clinincal trial information?

Study is for people with:

Multiple Sclerosis

Phase:

Phase 2

Estimated Enrollment:

340

Study ID:

NCT01226745

Recruitment Status:

Terminated

Sponsor:


EMD Serono

How clear is this clinincal trial information?

Clinical Trial Resources

Why I’d Choose a Clinical Trial For Myself
SurvivorNet’s Guide To Clinical Trials: What Are They And Are They Right for You?
Clinical Trials Can be Life-Saving for Some
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider